Given that abnormal TDP-43 is present in over 90% of ALS patients, therapeutics capable of clearing pathological TDP-43 may hold promise as universal treatments for diverse forms of the condition. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.